Vivos Therapeutics Buys 11% of SOD Sciences, Gains 50% Stake in Diagnostic Test

05:54 PM EDT, 10/19/2026 (MT Newswires) -- Vivos Therapeutics (VVOS) acquired an 11% fully diluted equity interest in SOD Sciences and a 50% co-ownership stake in SOD's pseudohypoxia early-warning diagnostic test. Vivos said Monday it issued 12,000 shares of series C convertible preferred stock with a stated value of $12 million as consideration, with no cash exchanged. Vivos said it expects to jointly market the test with SOD and potentially access American Health Associates' network, subject to pending agreements and bankruptcy-court approval. The company added that it is entitled to 50% of the contribution margin on sales of the test through any channel.